Genotyping Core The Genotyping Core provides investigators comprehensive services in genotyping a broad range of transgenic and mutant mouse strains in a fast and accurate manner that is critical to the analysis and interpretation of the data. The generation of conditional deletion of genes involves a complex breeding pattern and creates multiple lines. Accurate genotyping is vital to validate the successful targeted gene or genes to identify the final genotypes. Efficient and timely analysis of mouse genotypes greatly facilitates the management of PI mouse colonies and allows for the culling of unwanted genotypes in a timely fashion. This process expedites the PIs to manage their mouse lines and reduce the costs of housing. The Genotyping Core allows us to take much of the burden of genotyping multiple lines from lab personnel and to streamline and better maintain our mouse colonies. A second major advantage is the expertise of screening for genetic polymorphisms expressed in several inbred mouse lines that can impact the results of our work, e.g., rd1 and rd8 mutations and rpe65 polymorphisms. The Genotyping Core is especially helpful to the junior investigators who may not have this expertise in their lab and cannot afford to hire someone for this service. Furthermore, multiple genotyping requires different protocols to analyze the genotypes: different protocols are a time- consuming exercise. The core will standardize these protocols for the PI and provide support to scientists in their genotyping projects in every aspect of research, including planning, extracting DNA, genotyping, interpreting data, and doing statistical analysis.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Center Core Grants (P30)
Project #
5P30EY021725-07
Application #
9346078
Study Section
Special Emphasis Panel (ZEY1)
Project Start
Project End
Budget Start
2017-09-01
Budget End
2018-08-31
Support Year
7
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Oklahoma Health Sciences Center
Department
Type
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Royer, Derek J; Elliott, Michael H; Le, Yun Z et al. (2018) Corneal Epithelial Cells Exhibit Myeloid Characteristics and Present Antigen via MHC Class II. Invest Ophthalmol Vis Sci 59:1512-1522
Yang, Fan; Ma, Hongwei; Butler, Michael R et al. (2018) Deficiency of type 2 iodothyronine deiodinase reduces necroptosis activity and oxidative stress responses in retinas of Leber congenital amaurosis model mice. FASEB J :fj201800484RR
Rajala, Raju V S; Rajala, Ammaji (2018) Redundant and Nonredundant Functions of Akt Isoforms in the Retina. Adv Exp Med Biol 1074:585-591
Yang, Fan; Ma, Hongwei; Boye, Sanford L et al. (2018) Overexpression of Type 3 Iodothyronine Deiodinase Reduces Cone Death in the Leber Congenital Amaurosis Model Mice. Adv Exp Med Biol 1074:125-131
Tarantini, Stefano; Valcarcel-Ares, M Noa; Yabluchanskiy, Andriy et al. (2018) Nrf2 Deficiency Exacerbates Obesity-Induced Oxidative Stress, Neurovascular Dysfunction, Blood-Brain Barrier Disruption, Neuroinflammation, Amyloidogenic Gene Expression, and Cognitive Decline in Mice, Mimicking the Aging Phenotype. J Gerontol A Biol Sci Med Sci 73:853-863
Coburn, Phillip S; Miller, Frederick C; LaGrow, Austin L et al. (2018) TLR4 modulates inflammatory gene targets in the retina during Bacillus cereus endophthalmitis. BMC Ophthalmol 18:96
Sharif, Rabab; Priyadarsini, Shrestha; Rowsey, Tyler G et al. (2018) Corneal Tissue Engineering: An In Vitro Model of the Stromal-nerve Interactions of the Human Cornea. J Vis Exp :
Rajala, Ammaji; Wang, Yuhong; Rajala, Raju V S (2018) Constitutive Activation Mutant mTOR Promote Cone Survival in Retinitis Pigmentosa Mice. Adv Exp Med Biol 1074:491-497
Reagan, Alaina M; Gu, Xiaowu; Paudel, Sijalu et al. (2018) Age-related focal loss of contractile vascular smooth muscle cells in retinal arterioles is accelerated by caveolin-1 deficiency. Neurobiol Aging 71:1-12
Wang, Yuhong; Rajala, Ammaji; Rajala, Raju V S (2018) Nanoparticles as Delivery Vehicles for the Treatment of Retinal Degenerative Diseases. Adv Exp Med Biol 1074:117-123

Showing the most recent 10 out of 146 publications